Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology

Next-generation oncolytic viruses (OVs) represent a breakthrough in cancer immunotherapy by acting as in situ cancer vaccines that induce broad T cell responses independent of pre-existing tumour-specific T cells. Clinical data show their potential to overcome resistance to immune checkpoint inhibitors, establishing OVs as foundational platforms in immuno-oncology with strategies to prime and amplify antitumour immunity.

This Wire brief sits within Fusion42's coverage of Biotech.